Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of social anxiety disorder comprises epidemiological estimates of key patient populations across seven countries worldwide. We report the prevalence of social…

The number of total prevalent cases of SAD in the countries under study will increase by 7% from 21 million to 23 million in 20 years. Of the countries considered in this analysis, the total…

Clarivate Epidemiology’s coverage of community-acquired bacterial pneumonia (CABP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…

Eisai / Biogen’s Leqembi (lecanemab) has launched for the treatment of early AD in the United States and Japan. However, it is facing challenges in Europe, including a negative opinion from the…

The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira,…

The major depressive disorder (MDD) therapy market is crowded and highly genericized. The prominent use of generic drugs such as selective serotonin reuptake inhibitors (SSRIs) as early-line…

The treatment of neuropathic pain involves the use of drugs from several classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid…

The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira,…

Clarivate Epidemiology’s coverage of autism spectrum disorder (ASD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Renal anemia is a common complication of chronic kidney disease (CKD). The primary goal of treatment of renal anemia is to increase and maintain Hb levels and reduce the risk of complications of…

The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics and targeted oral therapies. The well-established TNF-α…

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Pirfenidone was the first disease-modifying therapy (DMT) approved for IPF,…